{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:12:27Z","timestamp":1788671547620,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp; Dementia"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>\n                      ABvac40 is an active immunotherapy targeting A\n                      <jats:italic>\u03b2<\/jats:italic>\n                      40, the main component of cerebrovascular deposition in Alzheimer's disease (AD). A 24\u2010month randomized, placebo\u2010controlled phase 2 study (Part A) showed favorable safety and robust immunogenicity, with exploratory signals of clinical efficacy. Here, we report results from Part B, an 18\u2010month extension evaluating long\u2010term safety and immunological memory.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Participants treated with ABvac40 in Part A received placebo plus a delayed booster, whereas previous placebo participants received ABvac40. Exploratory endpoints included safety, tolerability, and immunogenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Seventy\u2010seven participants entered Part B. Treatment\u2010emergent adverse events (TEAEs) occurred in 75.0% of participants in placebo + booster group and 81.1% in ABvac40 group; serious TEAEs were 5.0% and 16.2%, respectively. No ARIA\u2010E or meningoencephalomyelitis were observed, with one ARIA\u2010H event. ABvac40 induced robust antibody responses following delayed booster, with detectable anti\u2010A\n                      <jats:italic>\u03b2<\/jats:italic>\n                      40 antibodies in CSF.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>ABvac40 showed favorable long\u2010term safety and durable immunogenicity, supporting further clinical development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION<\/jats:title>\n                    <jats:p>ClinicalTrials.gov: NCT03461276, registered March 2, 2018. EudraCT: 2016\u2010004352\u201030, registered March 10, 2017.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/alz.71746","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:35:18Z","timestamp":1786599318000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long\u2010term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study"],"prefix":"10.1002","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4638-3153","authenticated-orcid":false,"given":"Mar\u00eda","family":"Pascual\u2010Lucas","sequence":"first","affiliation":[{"name":"R&amp;D, Araclon Biotech\u2010Grifols  Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Lacosta","sequence":"additional","affiliation":[{"name":"R&amp;D, Araclon Biotech\u2010Grifols  Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Monta\u00f1\u00e9s","sequence":"additional","affiliation":[{"name":"R&amp;D, Araclon Biotech\u2010Grifols  Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Canudas","sequence":"additional","affiliation":[{"name":"R&amp;D, Araclon Biotech\u2010Grifols  Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Loscos","sequence":"additional","affiliation":[{"name":"R&amp;D, Araclon Biotech\u2010Grifols  Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Monle\u00f3n","sequence":"additional","affiliation":[{"name":"R&amp;D, Araclon Biotech\u2010Grifols  Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Allu\u00e9","sequence":"additional","affiliation":[{"name":"R&amp;D, Araclon Biotech\u2010Grifols  Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Sarasa","sequence":"additional","affiliation":[{"name":"R&amp;D, Araclon Biotech\u2010Grifols  Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Fandos","sequence":"additional","affiliation":[{"name":"R&amp;D, Araclon Biotech\u2010Grifols  Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Romero","sequence":"additional","affiliation":[{"name":"R&amp;D, Araclon Biotech\u2010Grifols  Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Sarasa","sequence":"additional","affiliation":[{"name":"R&amp;D, Araclon Biotech\u2010Grifols  Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Torres","sequence":"additional","affiliation":[{"name":"Scientific Innovation Office, Grifols  Sant Cugat del Vall\u00e8s Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dermot","family":"Whyms","sequence":"additional","affiliation":[{"name":"Biometry, GrifolsWorldwide Operations Limited, Clondalkin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Terencio","sequence":"additional","affiliation":[{"name":"R&amp;D, Araclon Biotech\u2010Grifols  Zaragoza Spain"},{"name":"Scientific Innovation Office, Grifols  Sant Cugat del Vall\u00e8s Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Pi\u00f1ol\u2010Ripoll","sequence":"additional","affiliation":[{"name":"Cognition and Behaviour Study Group Institut de Recerca Biom\u00e8dica de Lleida \u2013 Fundaci\u00f3 Dr. Pifarr\u00e9, IRBLleida  Lleida Spain"},{"name":"Unitat de Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida Universitat de Lleida, IRBLleida  Lleida Spain"},{"name":"Department of Experimental Medicine, Faculty of Medicine Universitat de Lleida (UdL)  Lleida Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[{"name":"Ace Alzheimer Center Barcelona \u2013 Universitat Internacional de Catalunya  Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Neurodegenerativas (CIBERNED) Instituto de Salud Carlos III  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"202","article-title":"Active immunization targeting amyloid \u03b2 for the treatment of Alzheimer's disease","volume":"25","author":"Triplett O","year":"2025","journal-title":"Neurodegener Dis"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010019\u20100281\u20102"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12366"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000441919"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002175"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(00)03589\u20103"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.11.1629"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22112"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010024\u201001053\u20108"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad188"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70776"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010018\u20100340\u20108"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304430"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0065"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A8469"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.12.004"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010025\u201008728\u20102"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2018.10.010"},{"key":"e_1_2_9_27_1","first-page":"103","article-title":"Results from a phase II study to assess the clinical and immunological activity of AFFITOPE\u00ae AD02 in patients with early Alzheimer's disease","volume":"2","author":"Schneeberger A","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_9_28_1","first-page":"10","article-title":"Active A\u03b2 immunotherapy CAD106 in Alzheimer's disease: a phase 2b study","volume":"3","author":"Vandenberghe R","year":"2017","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0983"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104665"},{"key":"e_1_2_9_31_1","unstructured":"AlzinovaABA study on the safety tolerability and immunogenicity of ALZ\u2010101 in participants with early Alzheimer's disease. Accessed 19 February 2026. doi:https:\/\/clinicaltrials.gov\/NCT05328115"},{"key":"e_1_2_9_32_1","unstructured":"Phase I Clinical Study of AV\u20101959R: Abeta\u2010targeting Anti\u2010Alzheimer's Vaccine. Accessed 19 February 2026. doi:https:\/\/clinicaltrials.gov\/NCT06831812"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71746","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.71746","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:22:04Z","timestamp":1788668524000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.71746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/alz.71746"],"URL":"https:\/\/doi.org\/10.1002\/alz.71746","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71746"}}